# The Cooper Companies Inc. (COO) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $60.83, market value $11.6 billion.

## Valuation
- **P/E (trailing): 20.9×** (5-yr avg 37.1×, 3-yr avg 47.8×). The Cooper Companies Inc. trades at 20.9× trailing earnings, well below its own five-year average of 37.1×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.0×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 2.7×**. Each dollar of revenue is priced at 2.7×.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 15.0×**. Enterprise value is 15.0× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.9%** (5-yr avg 2.3%). Free cash flow equals 5.9% of the market value, above its five-year average of 2.3%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 4.8%**. The inverse of the P/E: 4.8% of the price is earned each year.

## Profitability
- **Gross margin: 65.9%**. The Cooper Companies Inc. keeps 65.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 12.8%**. 12.8% of revenue is left after running the business.
- **Net margin: 9.2%**. 9.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 4.6%**. 4.6% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 4.0%**. Return on all capital, debt included, is 4.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 4.6%**. Each dollar of assets produces 4.6% of profit.

## Growth
- **Revenue growth (1 yr): 5.1%** (3-yr 7.3%/yr, 5-yr 11.0%/yr). Revenue grew 5.1% over the last year, against 11.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -4.6%** (3-yr -1.2%/yr, 5-yr 9.2%/yr). Earnings per share fell 4.6%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -1.3%/yr**. Free cash flow has compounded at -1.3% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.30**. Debt is 0.30 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.6×**. It would take 2.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 1.89** (quick 1.89). Current assets cover the next year's liabilities 1.89 times.
- **Altman Z-score: 3.21**. A Z-score of 3.21 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. The Cooper Companies Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (15 analysts). 15 analysts cover The Cooper Companies Inc.; the consensus is buy, with an average price target of $65.80 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -12.3%** (YTD -25.2%, 3-mo -17.4%). The shares are down 12.3% over twelve months including dividends.
- **From 52-week high: -32.3%** (19.3% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 0.45** (volatility 32%). Beta of 0.45 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=COO · Page: https://foliofundamentals.com/stocks/coo

Not investment advice.